These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20153190)

  • 41. Stable extended human immunodeficiency virus type 1 gp41 coiled coil as an effective target in an assay for high-affinity fusion inhibitors.
    Cai L; Balogh E; Gochin M
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2444-9. PubMed ID: 19364877
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
    Zhu Y; Ding X; Yu D; Chong H; He Y
    J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis, Biological Evaluation, and Molecular Docking Studies of Novel 4-[4-Arylpyridin-1(4H)-yl]benzoic Acid Derivatives as Anti-HIV-1 Agents.
    Sepehri S; Soleymani S; Zabihollahi R; Aghasadeghi MR; Sadat M; Saghaie L; Fassihi A
    Chem Biodivers; 2017 Dec; 14(12):. PubMed ID: 28834275
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.
    Lai W; Wang C; Yan J; Liu H; Zhang W; Lin B; Xi Z
    Bioorg Med Chem; 2020 Feb; 28(4):115214. PubMed ID: 31932193
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure.
    Pang W; Wang RR; Gao YD; Yang LM; Sun Y; Huang JF; Tien P; Zheng YT
    J Biomol Screen; 2011 Feb; 16(2):221-9. PubMed ID: 21297108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652.
    Chong H; Yao X; Qiu Z; Qin B; Han R; Waltersperger S; Wang M; Cui S; He Y
    J Biol Chem; 2012 Jun; 287(24):20281-9. PubMed ID: 22511760
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Paramagnetic relaxation assisted docking of a small indole compound in the HIV-1 gp41 hydrophobic pocket.
    Gochin M; Zhou G; Phillips AH
    ACS Chem Biol; 2011 Mar; 6(3):267-74. PubMed ID: 21155611
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CD4 mimics targeting the mechanism of HIV entry.
    Yamada Y; Ochiai C; Yoshimura K; Tanaka T; Ohashi N; Narumi T; Nomura W; Harada S; Matsushita S; Tamamura H
    Bioorg Med Chem Lett; 2010 Jan; 20(1):354-8. PubMed ID: 19926478
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41.
    Cai L; Jiang S
    ChemMedChem; 2010 Nov; 5(11):1813-24. PubMed ID: 20845360
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potential HIV-1 fusion inhibitors mimicking gp41-specific broadly neutralizing antibody 10E8: In silico discovery and prediction of antiviral potency.
    Andrianov AM; Kashyn IA; Tuzikov AV
    J Bioinform Comput Biol; 2018 Apr; 16(2):1840007. PubMed ID: 29439644
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability.
    Pan C; Cai L; Lu H; Lu L; Jiang S
    J Biol Chem; 2011 Aug; 286(32):28425-34. PubMed ID: 21690094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy.
    Garg H; Viard M; Jacobs A; Blumenthal R
    Curr Top Med Chem; 2011 Dec; 11(24):2947-58. PubMed ID: 22044225
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.
    Yi HA; Fochtman BC; Rizzo RC; Jacobs A
    Curr HIV Res; 2016; 14(3):283-94. PubMed ID: 26957202
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors.
    Katritzky AR; Tala SR; Lu H; Vakulenko AV; Chen QY; Sivapackiam J; Pandya K; Jiang S; Debnath AK
    J Med Chem; 2009 Dec; 52(23):7631-9. PubMed ID: 19746983
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
    J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Design, synthesis and activity assessment of aryl-substituent benzyl acid targeting HIV gp41].
    Wang H; Chen Z; Qiu J; Yu X; Xie Y; Liu S
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Feb; 33(2):221-4. PubMed ID: 23443776
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of a beta3-peptide HIV fusion inhibitor with improved potency in live cells.
    Bautista AD; Stephens OM; Wang L; Domaoal RA; Anderson KS; Schepartz A
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3736-8. PubMed ID: 19497744
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1.
    Debnath AK; Radigan L; Jiang S
    J Med Chem; 1999 Aug; 42(17):3203-9. PubMed ID: 10464007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
    Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
    Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.